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Abstract: The reaction of a series of 1,2-diols with thionyl chloride led to bisnoradamantane sulfites in very good yields. 
The reaction has also been applied to related polycyclic scaffolds. The compounds have been tested for antiviral activity 
but none of them showed to be active. Several attempts to generate and trap SO from these polycyclic sulfites have been 
unsuccessful. 
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INTRODUCTION 
Derivatives of adamantane are of significant interest in 
medicinal chemistry. Amantadine and rimantadine have been 
used for years as anti-influenza A agents [1], and a dimethyl 
derivative of amantadine, memantine, is a NMDA receptor 
antagonist clinically used for the treatment of Alzheimer’s 
disease [2]. Recently, structurally more complex adamantane 
derivatives have been introduced into the clinic, such as the 
dipeptidil peptidase IV (DPP-IV) inhibitors vildagliptin and 
saxagliptin, of interest for the treatment of type 2 diabetes 

















Fig. (1). Adamantanes of clinical interest. 
It is well-known in medicinal chemistry that when drugs 
contain cyclic systems, it is generally worth synthesizing 
analogues where the ring is opened, expanded or contracted 
by one unit, because these analogues show similar activity to 
the parent compound [4]. For this reason, some time ago we 
started a program aimed to synthesize and pharmacologically 
evaluate a series of ring-contracted analogs of amantadine, 
memantine and rimantadine. We have already found that  
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several bisnoradamantane and noradamantane amines showed 
an interesting activity as NMDA receptor antagonists [5]. 
Very recently, Kolocouris et al. found that racemic ada-
mantane sulfite 1, is markedly active against vesicular sto-
matitis virus, its potency being 2.5-fold higher than that of 
the reference compound, (S)-9-(2,3-dihydroxypropyl)adenine 






Fig. (2). Antiviral adamantane sulfite 1. 
Some time ago, we described a short, inexpensive, high-
yielding synthesis of a series of bisnoradamantane pinacols 
of general structure 3 by pinacol coupling of diketones of 













Scheme 1. Synthesis of bisnoradamantane pinacols 3 from easily 
available diketones 2. 
Taking into account the easy access to pinacols of struc-
ture 3 and the potent anti-viral activity displayed by adaman-
tane sulfite 1, we undertook the synthesis and antiviral 
evaluation of sulfites derived from 3 and related pinacols as 
ring-contracted analogs of adamantane sulfite 1. 
RESULTS AND DISCUSSION 
Chemistry 
Reaction of known pinacol 3a with an excess of thionyl 
chloride led to sulfite 4a in 89% yield. The same procedure 
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was used for bisnoradamantane pinacols 3b-d, the corre-
sponding sulfites 4b-d being obtained. Moreover, starting 
from pinacols 5 and 7, sulfites 6 and 8 were obtained in 
quantitative yield (Scheme 2). Worthy of note, although 
pinacols 5 and 7 were known compounds [8], their previ-
ously described syntheses were somehow problematic and 
low-yielding. We have now found that both compounds are 
also easily available in essentially quantitative yield by the 
pinacol coupling of their corresponding diketones applying 
the same methodology that we had previously used for the 

































Scheme 2. Synthesis of new bisnoradamantane sulfites 4a-d, 
noradamantane derivative 6 (65%) and related compound 8 (65% 
yield). 4a (R=R’=CH3; 89% yield), 4b (R,R’=-(CH2)4-; 66% yield), 
4c (R=CH3, R’=C6H5; 71% yield), 4d (R,R’=2,2’-biphenylene; 
67% yield). 
The new polycyclic sulfites described herein are easily 
accessible and, with the only exception of 4c, achiral com-
pounds, thus avoiding issues related to the different pharma-
cological activity that may be associated with the two enan-
tiomers of chiral compounds, such as sulfite 1. The structure 
of all new compounds was confirmed by elemental analysis 
or accurate mass measurement, IR, 1H NMR, 13C NMR and 
mass spectral data. 
We have previously found that bisnoradamantane pina-
cols 3 were not very stable, undergoing ring-opening proc-
esses to bicyclic derivatives. These processes were explained 
taking into account the large strain released during the open-
ing of the strained bisnoradamantane skeleton to a bicy-
clo[3.3.0]octane derivative [9]. 
Taking into account these precedents we wondered about 
the possibility of using these new sulfites as a potential 
source of sulfur monoxide, SO, a very reactive species. Al-
though there are several methods for SO production, the 
search for an effective source has proven to be a challenging 
problem as most of the reported procedures only lead to 
trapped products in very low yields [10]. In 2001, Grainger 
and coworkers reported a convenient method for its genera-
tion and trapping, although the yield of the synthesis of the 
precursor, a naphthalene-derived trisulfide oxide, was modest 
[11]. 
Interestingly, adsorption of sulfite 4b in silica gel for 24 
hours at room temperature, followed by elution with hex-
ane/EtOAc led to a mixture of the starting sulfite and dike-
tone 2b. Besides, refluxing overnight a toluene solution of 
sulfite 4b furnished a mixture of diketone 2b, 4b and several 
minor impurities. Encouraged by these results, we investi-
gated the potential of sulfites 4 to act as a source of sulfur 
monoxide in trapping experiments with dienes. However, 
refluxing a solution of sulfite 4b in chlorobenzene with ex-
cess isoprene gave no evidence for the formation of sulfox-
ide 9, although formation of diketone 2b was again ob-
served. Although several attempts involving thermal and 
acidic conditions were explored, no evidences for the genera-
tion of SO were found. Sulfoxide 9 was not detected even 
when the thermally induced decomposition was carried out 
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Scheme 3. Unsuccessful attempt to generate and trap SO from sul-
fites 4. 
So far, we do not have a conclusive explanation for the 
opening of the sulfites to the corresponding diketones. Per-
haps, the decomposition of these sulfites involves oxidation 
to their corresponding sulfates, followed by SO2 extrusion. 
In fact, we have previously found that the sulfate derived 
from pinacol 4a underwent thermally induced conversion to 
the corresponding diketone [12]. 
Antiviral Assays 
None of the six tested sulfites displayed activity against 
the enveloped DNA viruses herpes simplex virus (type 1 or 
type 2) or vaccinia virus; the enveloped RNA viruses feline 
coronavirus, parainfluenza-3 virus, respiratory syncytial vi-
rus, vesicular stomatitis virus, sindbis virus or Punta Toro 
virus; or the non-enveloped RNA viruses Coxsackievirus B4 
and Reovirus-1. Also, none of the compounds was found to 
be active against influenza virus A/H1N1, A/H3N2 or B. 
CONCLUSIONS 
Six new polycyclic sulfites have been synthesized from 
easily available pinacols. Several attempts to trap sulfur 
monoxide from the decomposition of these sulfites met with 
failure. None of the sulfites displayed antiviral activity. Tak-
ing into account that the precursor of biologically active sul-
fite 1 features a primary and a secondary alcohol group and 
that the new sulfites reported herein are derived from tertiary 
alcohols, it seems that less steric congestion around the sul-
fite group is required for antiviral activity. The syntheses of 
this kind of sulfite from bisnoradamantane derivatives are 




Melting points were determined in open capillary tubes. 
Unless otherwise stated, NMR spectra were recorded in 
CD3OD in the following spectrometers: 1H NMR (500 
MHz), 13C NMR (75.4 MHz). Chemical shits (δ) are reported 
in ppm related to internal tetramethylsilane (TMS). Assign-
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ments given for the NMR spectra are based on DEPT, COSY 
1H/1H, HETCOR 1H/13C (HSQC and HMBC sequences for 
one bond and long range 1H/13C heterocorrelations, respec-
tively) and NOESY experiments for selected compounds. 
For the MS and GC/MS analyses the sample was introduced 
directly or through a gas chromatograph. For GC/MS analy-
ses a 30−meter column [5% diphenyl−95% dimethylpolysi-
loxane, conditions: 10 psi, initial temperature: 35 ºC (2 min), 
then heating at a range of 8 ºC/min till 300 ºC, then isother-
mic at 300 ºC] was used. The electron impact (70 eV) or 
chemical ionization (CH4) techniques were used. Only sig-
nificant ions are given: those with higher relative ratio, ex-
cept for the ions with higher m/z values. Accurate mass 
measurements were obtained using ESI technic. Absorption 
values in the IR spectra (KBr) are given as wave-numbers 
(cm−1). Only the more intense bands are given. Column 
chromatography was performed on silica gel 60 Å (35−70 
mesh). For the thin layer chromatography (TLC) aluminum-
backed sheets with silica gel 60 F254 were used and spots 
were visualized with UV light and/or 1% aqueous solution of 
KMnO4. 
Tricyclo[3.3.1.03,7]nonane-3,7-diol, (5) 
Powdered Zn (6.54 g, 100 mmol) was added portionwise 
at room temperature to a solution of TiCl4 (9.48 g, 50 mmol) 
in anhydrous 1,4-dioxane (75 mL). Pyridine (2.5 mL) was 
added and the mixture was heated at reflux for 1 h in an ar-
gon atmosphere. A solution of bicyclo[3.3.1]nonan-3,7-
dione (761 mg, 5 mmol) in anhydrous 1,4-dioxane (25 mL) 
was added dropwise with stirring and the mixture was heated 
at reflux for 18 h. The mixture was allowed to cool to room 
temperature and was slowly added to 30% aqueous solution 
of K2CO3 (250 mL), the final aqueous phase being alkaline. 
CH2Cl2 (300 mL) was added to the dark blue mixture, which 
was then filtered through Celite®. The two phases of the fil-
trate were separated and the aqueous one was extracted once 
with CH2Cl2 (300 mL). The combined organic phase and 
extract was washed with water, aqueous 2N HCl and brine, 
dried with anhydrous MgSO4, filtered and concentrated in 
vacuo to give a semisolid residue that was crystallized from 
CH2Cl2 to give pinacol 5 (732 mg, 95% yield). The spectro-




As described for 5, starting from 5,6,8,9,-tetrahydro-5,9-
propano-7H-benzocycloheptene-7,11-dione (1.50 g, 7.0 
mmol), pinacol 7 was obtained as a white solid (1.46 g, 
96.3% yield). The spectroscopic data of 7 were identical to 
those previously published [8]. 
3,7-Dimethyl-1,5-sulfinyldioxytricyclo[3.3.0.03,7]octane, (4a) 
Pinacol 3a (592 mg, 3.52 mmol) was solved in CH2Cl2 
(12 mL) at room temperature and thionyl chloride (0.42 mL, 
5.77 mmol) in CH2Cl2 (4.2 mL) was added dropwise. The 
solution was stirred at room temperature for 1 h and concen-
trated under reduced pressure to give a dark solid (754 mg) 
that was purified by column chromatography (pentane) to 
give sulfite 4a as a white solid (673 mg, 89% yield). An ana-
lytical sample of 4a was obtained by crystallization from 
EtOAc/hexane, mp 49-50 ºC (EtOAc/hexane); IR (KBr) ν 
2943, 2929, 2366, 1478, 1380, 1293, 1260, 1225, 1206, 
1168, 1033, 1010, 838, 794, 691, 519, 460 cm−1; 1H NMR δ: 
1.11 (s, 3 H) and 1.12 (s, 3H) [CH3-C(3) and CH3-C(7)], 
1.75 (dd, J = 7.5 Hz, J’ = 3.5 Hz, 2 H) [2(4)-Hα or 6(8)-Hα], 
1.92 (d, J = 7.5 Hz, 2 H) [2(4)-Hβ or 6(8)-Hβ], 2.00 (d, J = 
8.0 Hz, 2 H) [6(8)-Hβ or 2(4)-Hβ], 2.08 (dd, J = 8.0 Hz, J’ = 
3.5 Hz, 2 H) [6(8)-Hα or 2(4)-Hα]; 
13C NMR δ: 16.4 (CH3) 
and 16.5 (CH3) [CH3-C(3) and CH3-C(7)], 46.7 (C) and 46.9 
(C), (C3 and C7), 54.9 (CH2) and 56.2 (CH2) [C2(4) and 
C6(8)], 94.6 [C, C1(5)]. MS (EI), m/z (%): 214 ([M]·+, 1), 
150 ([M−SO2].+, 86), 135 (31), 133 (31), 132 (62), 131 (13), 
123 (18), 122 (16), 121 (20), 117 (50), 110 (10), 109 (24), 
108 (53), 107 (97), 105 (26), 95 (27), 94 (22), 93 (41), 91 
(42), 83 (37), 82 (28), 81 (26), 80 (12), 79 (41), 77 (21), 69 
(10), 68 (55), 67 (30), 65 (11), 55 (100), 52 (21), 77 (41), 69 
(100). Accurate mass measurement: calcd for C10H15O3S 
([M+H]+): 215.0736; found: 215.0740.  
3,7-Tetramethylene-1,5-sulfinyldioxytricyclo[3.3.0.03,7]octane, 
(4b) 
As described for 4a, starting from pinacol 3b (500 mg, 
2.57 mmol), sulfite 4b was obtained as a white solid (408 
mg, 66% yield). An analytical sample of 4b was obtained by 
crystallization from EtOAc/hexane, mp 69-70 ºC 
(EtOAc/hexane); IR (KBr) ν 2986, 2941, 2855, 1740, 1477, 
1457, 1289, 1264, 1225, 1203, 1116, 1080, 1010, 932, 799, 
693, 654, 528, 515 cm−1; 1H NMR δ: 1.57 (complex signal, 4 
H) [CH2CH2-C(3) and CH2CH2-C(7)], 1.65 (complex signal, 
4 H) [CH2-C(3) and CH2-C(7)], 1.78 (dd, J = 7.5 Hz, J’ = 3.5 
Hz, 2 H) [2(4)-Hα or 6(8)-Hα], 2.06-2.12 (complex signal, 4 
H) [2(4)-Hβ or 6(8)-Hβ and 6(8)-Hα or 2(4)-Hα], 2.19 (d, J = 
8.0 Hz, 2 H) [6(8)-Hβ or 2(4)-Hβ]; 
13C NMR δ: 17.9 (CH2) 
and 18.0 (CH2) [CH2CH2-C(3) and CH2CH2-C(7)], 25.0 
(CH2) and 25.1 (CH2) [CH2-C(3) and CH2-C(7)], 46.6 (C) 
and 46.8 (C), (C3 and C7), 52.5 (CH2) and 53.8 (CH2) 
[C2(4) and C6(8)], 94.4 [C, C1(5)]. MS (EI), m/z (%): 240 
([M]·+, 2), 192 ([M−SO].+, 14), 176 ([M−SO2].+, 40), 175 
(17), 164 (14), 162 (11), 161 (90), 150 (20), 149 (31), 148 
(48), 147 (48), 144 (11), 143 (10), 136 (17), 135 (27), 134 
(46), 133 (82), 131 (11), 122 (18), 121 (34), 120 (39), 119 
(38), 118 (13), 117 (14), 109 (12), 108 (54), 107 (58), 106 
(34), 105 (56), 96 (12), 95 (41), 94 (19), 93 (66), 92 (30), 91 
(100), 82 (15), 81 (23), 80 (24), 79 (89), 78 (14), 77 (51), 68 
(24), 67 (32), 65 (21), 55 (16), 53 (25). 
3-Methyl-7-phenyl-1,5-sulfinyldioxytricyclo[3.3.0.03,7]octane, 
(4c) 
As described for 4a, starting from pinacol 3c (539 mg, 
2.34 mmol), sulfite 4c was obtained as a white solid (460 
mg, 71% yield). An analytical sample of 4c was obtained by 
crystallization from EtOAc/hexane, mp 109-110 ºC 
(EtOAc/hexane); IR (KBr) ν 3037, 2997, 2956, 2919, 2897, 
2862, 1958, 1604, 1500, 1476, 1449, 1376, 1331, 1294, 
1262, 1206, 182, 1157, 1137, 1058, 1021, 992, 976, 913, 
840, 791, 757, 697, 687, 663, 583, 532, 511, 477 cm−1; 1H 
NMR δ: 0.77 [s, 3 H, CH3-C(3)], 1.90 (dd, J = 8.0 Hz, J’ = 
3.5 Hz, 2 H) [2(4)-Hα or 6(8)-Hα], 2.06 (d, J = 8.0 Hz, 2 H) 
[2(4)-Hβ or 6(8)-Hβ], 2.33 (dd, J = 8.0 Hz, J’ = 3.5 Hz, 2 H) 
[6(8)-Hα or 2(4)-Hα], 2.69 (d, J = 8.0 Hz, 2 H) [6(8)-Hβ or 
2(4)-Hβ], 7.20 (m, 2 H, Ar-Hortho), 7.27 (tt, 1 H, J = 7.5 Hz, 
J’ = 1.5 Hz, Ar-Hpara), 7.36 (m, 2 H, Ar-Hmeta); 13C NMR δ: 
18.4 [CH3, CH3-C(3)], 49.7 (C, C3), 54.2 (CH2) and 54.7 
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(CH2) [C2(4) and C6(8)], 55.0 [C, C1(5)], 94.5 (C, C7), 
126.8 (CH, Cpara), 127.9 (CH, Cortho), 128.2 (CH, Cmeta), 
139.0 (C, Cipso). MS (EI), m/z (%): 276 ([M]·+, 1), 228 
([M−SO].+, 1), 212 ([M−SO2].+, 4), 195 (31), 194 (100), 193 
(11), 179 (24), 170 (14), 169 (20), 141 (12), 129 (11), 128 
(14), 117 (22), 115 (31), 91 (20), 77 (10), 55 (13). Anal. 
Calcd for C15H16O3S (276.35): C 65.19, H 5.84, S 11.60. 
Found: C 65.26, H 5.81, S 11.43. 
3,7-(2,2’-Biphenylene)-1,5-sulfinyldioxytricyclo[3.3.0.03,7] 
octane, (4d) 
As described for 4a, starting from pinacol 3d (700 mg, 
2.41 mmol), sulfite 4d was obtained as a white solid (543 
mg, 67% yield). An analytical sample of 4d was obtained by 
crystallization from EtOAc/hexane, mp 178-179 ºC 
(EtOAc/hexane); IR (KBr) ν 2925, 1442, 1275, 1257, 1205, 
1153, 1109, 1078, 998, 928, 794, 757, 728, 690, 546, 507 
cm−1; 1H NMR δ: 2.38 (dd, J = 8.0 Hz, J’ = 4.0 Hz, 2 H) 
[2(4)-Hα or 6(8)-Hα], 2.44 (d, J = 8.0 Hz, 2 H) [2(4)-Hβ or 
6(8)-Hβ], 2.53 (d, J = 8.0 Hz, 2 H) [6(8)-Hβ or 2(4)-Hβ], 2.71 
(dd, J = 8.0 Hz, J’ = 4.0 Hz, 2 H) [6(8)-Hα or 2(4)-Hα], 7.14-
7.23 (complex signal, 6 H, Ar-H), 7.83-7.88 (complex sig-
nal, 2 H, Ar-H); 13C NMR δ: 47.9 (C) and 48.1 (C), (C3 and 
C7), 56.4 (CH2) and 57.7 (CH2) [C2(4) and C6(8)], 93.7 [C, 
C1(5)], 123.1 (CH), 123.2 (CH), 127.2 (CH), 127.3 (CH), 
127.5 (CH), 127.6 (CH), 128.4 (CH) and 128.6 (CH) (Ar-
CH), 130.4 (C), 130.6 (C), 134.6 (C) and 134.7 (C) (Ar-C). 
MS (EI), m/z (%): 288 ([M−SO].+, 72), 232 (20), 231 (100), 
215 (10), 204 (30), 203 (77), 202 (45), 189 (10), 101 (10). 
Anal. Calcd for C20H16O3S·0.5C6H14 (379.49): C 72.80, H 
6.11, S 8.45. Found: C 73.14, H 5.68, S 8.16. 
3,7-Sulfinyldioxytricyclo[3.3.1.03,7]nonane, (6) 
As described for 4a, starting from pinacol 5 (299 mg, 
1.94 mmol), sulfite 6 was obtained as a white solid (252 mg, 
65% yield). An analytical sample of 6 was obtained by crys-
tallization from EtOAc/hexane, mp 76-77 ºC (EtOAc/  
hexane); IR (KBr) ν 2949, 2880, 2858, 1459, 1340, 1304, 
1205, 1129, 1098, 997, 967, 938, 857, 833, 803, 778, 705, 
670, 627, 615, 486 cm−1; 1H NMR δ: 1.50 (tm, J = 2.5 Hz, 2 
H, 9-H2), 1.98-2.04 [complex signal, 4 H, 2(8)-H2 or 4(6)-
H2], 2.18 [dt, J = 11.5 Hz, J’ = 2.0 Hz, 2 H4(6)-Hα or 2(8)-
Hα], 2.46 [dm, J = 11.5 Hz, 2 H, 4(6)-Hβ or 2(8)-Hβ], 2.62-
2.67 (complex signal, 2 H, 1-H and 5-H); 13C NMR δ: 33.4 
(CH2, C9), 40.6 (CH) and 41.8 (CH) (C1 and C5), 48.3 
(CH2) and 50.2 (CH2) [C2(8) and C4(6)], 100.2 [C, C3(7)]. 
MS (EI), m/z (%): 200 ([M]·+, 1), 152 ([M−SO].+, 5), 142 
(12), 136 ([M−SO2].+, 57), 135 (100), 108 (14), 107 (10), 95 
(69), 94 (26), 93 (19), 92 (14), 91 (12), 79 (21), 78 (20), 77 
(11), 68 (18), 67 (33), 66 (11). Anal. Calcd for C9H12O3S 




As described for 4a, starting from pinacol 7 (1.46 g, 6.74 
mmol), sulfite 8 was obtained as a white solid (1.15 g, 65% 
yield). An analytical sample of 8 was obtained by crystalliza-
tion from EtOAc/hexane, mp 149-150 ºC (EtOAc/hexane); 
IR (KBr) ν 3062, 3018, 2978, 2867, 1488, 1454, 1312, 1281, 
1228, 1205, 1125, 1053, 937, 920, 864, 810, 765, 712, 685, 
671, 623, 597, 565, 526, 484, 465 cm−1; 1H NMR δ: 2.16 
[dd, 2 H, J = 12.5 Hz, J’ = 1.0 Hz, 6(12)-Hβ or 9(11)-Hβ], 
2.30 [dd, 2 H, J = 12.5 Hz, J’ = 1.0 Hz, 9(11)-Hβ or 6(12)-
Hβ], 2.45 [ddd, 2 H, J = 12.5 Hz, J’ = 6.5 Hz, J’’ = 3 Hz, 
6(12)-Hα or 9(11)-Hα], 2.98 [ddd, 2 H, J = 12.5 Hz, J’ = 6.5 
Hz, J’’ = 3 Hz, 9(11)-Hα or 6(12)-Hα], 3.53 (t, 1 H, J = 6.5 
Hz, 5-H or 10-H), 3.57 (t, 1 H, J = 6.5 Hz, 10-H or 5-H), 
7.16-7.20 (complex signal, 4 H, Ar-H); 13C NMR δ: 47.4 
(CH) and 48.4 (CH) (C5 and C10), 48.1 (CH2) and 49.9 
(CH2) [C6(12) and C9(11)], 105.5 [C, C7(8)], 127.0 (CH) 
and 127.1 (CH) (C1 and C4), 129.6 (CH) and 129.7 (CH) 
(C2 and C3), 142.6 (C) and 143.2 (C) (C4a and C10a). MS 
(EI), m/z (%): 262 ([M]·+, 62), 214 ([M−SO].+, 6), 204 (37), 
199 (12), 198 ([M−SO2].+, 56), 197 (57), 186 (12), 172 (22), 
169 (14), 157 (47), 156 (27), 155 (73), 153 (12), 144 (30), 
143 (15), 142 (17), 141 (56), 130 (37), 129 (100), 128 (92), 
127 (28), 116 (20), 115 (66), 77 (11). Anal. Calcd for 
C14H14O3S (262.32): C 64.10, H 5.38, S 12.22. Found: C 
64.08 H 5.41, S 12.03. 
Antiviral Evaluation 
The antiviral activity of the compounds was determined 
in established cell culture assays using a selection of DNA 
and RNA viruses, including three subtypes of influenza virus 
[A/Puerto Rico/8/34 (H1N1); A/Hong Kong/7/87 (H3N2) 
and B/Hong Kong/5/72] [13]. The compounds’ inhibitory 
effect on virus replication as well as their cytotoxicity were 
monitored by microscopical examination, and confirmed by 
the colorimetric MTS cell viability assay. 
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